Pfizer Roulette: Why Over 30 Percent of BioNTech Batches Were Ineffective
The Danish data shows what should never have happened: Identical product, completely different outcomes. Some batches cause illness. Some do — nothing at all. # In December 2025, Hamburg mathematics professor Hans-Juergen Bandelt published the first part of a three-part analysis on tkp.at. His starting point: the Danish study by Schmeling and Manniche, peer-reviewed and published in the European Journal of Clinical Investigation in 2023 [1]. His finding: More than 30% of BioNTech batches were practically ineffective — and the PEI knew it [2][3][4].